$9.43
-$0.13
(-1.36%)
Quote as of 4:00 PM EST on 02/10/12
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
Rigel Pharma Has More Room To Run
Two Rigel Pharma (RIGL) Lead Product Candidates Entered Trials in Q411
Rigel Pharmaceuticals initiates clinical trials for two product candidates
Rigel Pharmaceuticals reports Q2 EPS 38c vs. consensus 39c
Rigel Announces Initiation of Clinical Trials in Two Immunology Programs
The 2 Best-Performing Sectors Over the Last Decade
Covidien Spins Off Drug Company: 5 Drug Makers Hedge Funds Want Most
The New Pfizer: 6 Drug Companies With Bullish Short Trends
Rigel to Present at Oppenheimer Annual Healthcare Conference
Rigel Pharmaceuticals management to meet with BMO Capital
Rigel Pharma shares should be bought ahead of Oskira data, says BMO Capital
Rigel to Participate at Two Upcoming Investor Conferences
Rigel Pharma posts 3Q loss as revenue falls
Rigel Pharmaceuticals Inc. Reports Operating Results (10-Q)
Rigel Pharmaceuticals, Inc. (RIGL) Reports Q3 Loss of $0.25
Rigel Pharmaceuticals reports Q3 EPS (25c) vs. consensus (30c)
Rigel Announces Third Quarter 2011 Financial Results
Piper Jaffray's biotech and specialty pharma analysts hold a conference call
Jefferies Maintains a 'Buy' on Rigel Pharmaceuticals (RIGL); Update On R343 And Early Pipeline
Rigel Pharmaceuticals to host analyst and investor day
Rigel to Webcast Investor Day on October 13, 2011
Biotech Calendar: Key Dates for October
JPMorgan Starts Rigel Pharmaceuticals (RIGL) at Overweight
Rigel Pharmaceuticals initiated with an Overweight at JP Morgan
BMO Capital hosts an analyst Biotechnology/Industry conference call
Rigel Pharmaceuticals initiated with an Outperform at BMO Capital
Citigroup to host a conference
Vertex Arthritis Pill Shines in Mid-Stage Study
Better Late Than Never? Maybe.
Rigel to Present at Two Upcoming Investor Conferences
Rigel Pharmaceuticals on track for US/European NDA filing dates in 2013
Rigel Pharmaceuticals (RIGL) Posts Q2 Loss of 37c/Sh., Tops Views
Rigel Pharmaceuticals reports Q2 EPS (37c) vs. consensus (38c)
Rigel Announces Second Quarter 2011 Financial Results
Piper Jaffray's biotech and specialty pharma analysts hold a conference call
Rigel Pharmaceuticals management to meet with Collins Stewart
Rigel Pharmaceuticals management to meet with Wells Fargo
